CLINICAL AND PATHOGENETIC FEATURES OF PROLACTIN SECRETION DISORDERS IN REPRODUCTIVE-AGE WOMEN WITH AUTOIMMUNE THYROIDITIS
Keywords:
autoimmune thyroiditis; Hashimoto thyroiditis; prolactin; hyperprolactinemia; macroprolactin; monomeric prolactin; subclinical hypothyroidism; reproductive health.Abstract
Autoimmune thyroiditis (AIT) is a prevalent autoimmune thyroid disorder in women of reproductive age, and associated thyroid dysfunction may influence hypothalamic–pituitary regulation of prolactin (PRL). The clinical significance of this relationship remains uncertain in euthyroid and subclinical hypothyroid states, particularly when total circulating PRL is interpreted without assessment of its molecular fractions. This narrative review critically synthesizes evidence concerning thyroid autoimmunity, thyroid functional status, prolactin secretion, macroprolactinemia and reproductive manifestations, drawing on clinical studies, systematic reviews and professional recommendations. The most established mechanism is increased thyrotropin-releasing hormone stimulation of pituitary lactotrophs during primary hypothyroidism. A study published in 2025 reported higher mean PRL concentrations among reproductive-age women with AIT than among controls and in subclinical hypothyroidism compared with euthyroid AIT; however, the observational association does not establish causation. Routine PRL immunoassays may also detect macroprolactin, potentially leading to an overestimation of clinically relevant hyperprolactinemia. When indicated, polyethylene-glycol precipitation and interpretation of post-precipitation PRL against assay-specific reference intervals help distinguish predominant macroprolactinemia from elevated monomeric PRL. An integrated approach incorporating thyroid-stimulating hormone, free thyroxine, thyroid autoantibodies, PRL fractions, clinical symptoms and relevant confounders may improve diagnostic interpretation. Prospective studies using standardized sampling and fraction-specific PRL measurements are needed to establish the frequency and reproductive implications of these abnormalities.
References
1.Carafone L, Knutson AJ, Gigliotti BJ. A review of autoimmune thyroid diseases and their complex interplay with female fertility. Semin Reprod Med. 2024;42(3):178–192. doi:10.1055/s-0044-1795160.
2.Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391–397. doi:10.1016/j.autrev.2014.01.007.
3.Should we routinely assess ovarian reserve in girls and young women with autoimmune thyroid disease? Heliyon. 2024;10(22):e40156. doi:10.1016/j.heliyon.2024.e40156.
4.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288. doi:10.1210/jc.2010-1692.
5.Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19:722–740. doi:10.1038/s41574-023-00886-5.
6.Glezer A, Elias PCL, Nogueira VSN, et al. Position statement on macroprolactinemia from the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC/ML). Arch Endocrinol Metab. 2025;69(6):e250152. doi:10.20945/2359-4292-2025-0152.
7.Glezer A, Garmes HM, Kasuki L, et al. Diagnosis of hyperprolactinemia in women: a Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2024;68:e230502. doi:10.20945/2359-4292-2023-0502.
8.Glezer A, Garmes HM, Kasuki L, et al. Hyperprolactinemia in women: diagnostic approach. Rev Bras Ginecol Obstet. 2024;46:e-FPS04. doi:10.61622/rbgo/2024FPS04.
9.Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and autoimmunity: the hormone as an inflammatory cytokine. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101324. doi:10.1016/j.beem.2019.101324.
10.Buldygina YV, Beliakova YI, Vatsyk MM, Terekhova HM. The correlation between thyroid status parameters and prolactin levels in reproductive-age women with autoimmune thyroiditis and subclinical hypothyroidism. Int J Endocrinol (Ukraine). 2025;21(2):160–166. doi:10.22141/2224-0721.21.2.2025.1514.
11.Phillipps HR, Yip SH, Grattan DR. Patterns of prolactin secretion. Mol Cell Endocrinol. 2020;502:110679. doi:10.1016/j.mce.2019.110679.
12.Wang R, Lv Y, Dou T, et al. Autoimmune thyroid disease and ovarian hypofunction: a review of literature. J Ovarian Res. 2024;17:125. doi:10.1186/s13048-024-01451-y.
13.Ramadras DD, Che Soh Yusof NAA, Yaacob NM, et al. Correlation of serum prolactin and thyroid stimulating hormone concentration in infertile women: a systematic review and meta-analysis. Malays J Med Sci. 2024;31(1):14–32. doi:10.21315/mjms2024.31.1.2.
